Q2 saw better-than-expected revenue, earnings, and cash flow, with strong life sciences and diagnostics performance. Raised full-year guidance for core revenue growth and adjusted EPS, supported by early Masimo acquisition and robust order trends, despite bioprocessing shipment delays.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.